Liquidia Corporation
LQDA
Rank in Stocks
#4848
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Share Price
$34.12
Last synced: 2026-10-19
Market Cap
$3.05B
Change (1 day)
-0.67%
Change (1 year)
39.61%
Country
US
Trade Liquidia Corporation (LQDA)
Category
Healthcare
P/S ratio for Liquidia Corporation (LQDA)
P/S ratio as of October 2026 TTM: 6.74
According to Liquidia Corporation latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 6.74. At the end of 2023 the company had a P/S ratio of 44.71.
P/S ratio history for Liquidia Corporation from 2016 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 6.74 | -89.81% |
| 2024 | 66.13 | 47.92% |
| 2023 | 44.71 | 83.47% |
| 2022 | 24.37 | 29.46% |
| 2021 | 18.82 | -86.07% |
| 2020 | 135.16 | 1,280.87% |
| 2019 | 9.79 | -82.92% |
| 2018 | 57.32 | 336.47% |
| 2017 | 13.13 | 82.10% |
| 2016 | 7.21 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.31 | 53.04% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 124.46% |
US
|
